neurological

Study: Cannabis Component Reduces Seizures For Some Epilepsy Patients, According To Research

NYU Langone Center

By Michael Bachara
Hemp News

An oil derived from the cannabis plant sharply reduces violent seizures in young people according to a study published last Wednesday in the New England Journal of Medicine. The study focused on patients with Dravet syndrome, a severe type of epilepsy.

"This is the first solid, rigorously obtained scientific data that a marijuana compound is safe and effective for this problem," said Dr. Orrin Devinsky, a neurologist at New York University Langone Medical Center and primary author of the study.

Wisconsin: Company Readies Hemp-Based Non-Prescription Cannabinoid Medication For Epilepsy

PuraMedBioScience(logo)

PuraMed BioScience, Inc., a company which researches, develops, and markets over-the-counter (OTC) medicinal and healthcare products on Friday announced it is nearing the completion of development of its new non-prescription, hemp-based, homeopathic medication for treatment of epilepsy symptoms including seizures and seizure-related headaches.

Both epilepsy and migraines appear to be triggered by the same cortical spreading depression (CSD) in the brain; the difference is the rate of reaction. This may be why many people who suffer from migraines are prescribed epilepsy medications.

The third most common neurological disorder in the US, epilepsy affects about 2.7 million people, with children and older adults being most susceptible. The condition also causes up to 50,000 sudden deaths each year.

Recent research has shown cannabidiol (CBD), a non-psychoactive cannabinoid found in both hemp and marijuana varieties of cannabis, to be an effective therapy in the treatment of epilepsy symptoms.

"By incorporating standardized hemp oil into our current patented, over-the-counter migraine relief formula, MigraPure, we believe we can offer relief to people who not only suffer with migraines, but also offer relief to people who have seizure-related headaches and other epilepsy-type symptoms," said Russ Mitchell, CEO at PuraMed BioScience.

Syndicate content